500 million men suffer from erectile dysfunction and premature ejaculation worldwide. Dicot is developing a modern potency drug with the ambition of creating a therapeutic drug that has a longer lasting effect and fewer side effects than those found on the market today.
News | 2024-10-22
Dicot Pharma attracts great attention at SMSNA, the US´s largest conference in sexual medicine
"It’s been a quarter-century of wait for a new class of oral medications for erectile dysfunction. The assembled experts at SMSNA, particularly those involved in the original Viagra research, clearly understood that a strong signal had emerged from the phase 01 study, that the wait is finally over and that the entire treatment regimen for erectile dysfunction may soon be revolutionized”, comments Dr. Harin Padma-Nathan.
Read More >Dicot Pharma to Nasdaq First North
News | 2024-09-04
Unit issue subcribed to 124%!
“With this fine outcome, we can, backed by a strong financial position, take the potency drug candidate LIB-01 through the proof of concept phase, while also investing in the development of new indications”, says CEO Elin Trampe
Read More >
The global market for treating sexual dysfunctions is annually worth around 8 billion USD and will increase due to underlying causes such as growing number of elderly
Today's potency drugs were launched over twentyfive years ago and have limitations
Up to 35% of men with erection problems do not respond to current treatments. LIB-01 works differently and opens up the possibility of being helped
Existing drugs have a duration of action of maximum 36 hours. According to studies, LIB-01 can have an effect lasting at least seven days
Sexual medicine experts states that there is a great need for new potency drugs
In Sweden only one out of four seeks medical help for erectile dysfunction due to the condition's stigma
The ambition with LIB-01
- Longer duration
- Effective for everyone
- Minimal side-effects
